Acadia Pharmaceuticals Inc. focuses on developing treatments for underserved neurological disorders and rare diseases. Its clinical-stage programs primarily target Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with early-stage initiatives addressing other unmet patient needs. The company is also seeking approval for a treatment option for Rett syndrome in Europe.
